|Dr. Richard Spencer Treagus BScMed, MBChB, MPharmMed, MBA||Exec. Chairman||341k||N/A||N/A|
|Mr. Lawrence Glass BA (Biology)||Chief Science Officer & Exec. Director||420k||N/A||N/A|
|Mr. Jonathan Charles Pilcher BSc (Hons), ACA||CFO & Company Sec.||N/A||N/A||N/A|
|Dr. Nancy E. Jones Ph.D.||VP of Clinical Devel.||N/A||N/A||N/A|
|Mr. James Shaw BSc (Hons), MBA||VP of Clinical Operations||N/A||N/A||N/A|
Neuren Pharmaceuticals Limited, a biopharmaceutical company, focuses on the development of therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its lead product is Trofinetide, which is in Phase II clinical trials for use in the treatment of Rett syndrome, Fragile X syndrome, moderate to severe traumatic brain injury, and concussion. The company is also developing NNZ-259 that is in preclinical development for the treatment of various neurological disorders. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Port Melbourne, Australia.
Neuren Pharmaceuticals Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.